How has the central nervous system (cns) lymphoma market evolved, and where is it heading next?
The central nervous system (CNS) lymphoma market size has grown strongly in recent years. It will grow from $1.44 billion in 2024 to $1.54 billion in 2025 at a compound annual growth rate (CAGR) of 7.0%. The growth in the historical period can be attributed to increased awareness and diagnosis, rising incidence of lymphoma, a growing number of clinical trials, increased funding for cancer research, and a rise in the use of biomarkers for targeted treatments.
The central nervous system (CNS) lymphoma market size is expected to see strong growth in the next few years. It will grow to $1.99 billion in 2029 at a compound annual growth rate (CAGR) of 6.6%. The growth in the forecast period can be attributed to the growing adoption of immunotherapy, increasing focus on targeted treatments, rising prevalence of CNS lymphoma, increased patient access to healthcare, government support, and initiatives. Major trends in the forecast period include the integration of artificial intelligence in diagnostics, the development of next-generation monoclonal antibodies, a shift towards less invasive treatments, advances in precision medicine, and advancements in diagnostic technologies.
Get Your Free Sample of The Global Central Nervous System (CNS) Lymphoma Market Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=21133&type=smp
What are the key drivers behind the rapid expansion of the central nervous system (cns) lymphoma market?
The increasing incidences of psychological disorders are expected to propel the growth of the central nervous system (CNS) lymphoma market going forward. Psychological disorders are mental health conditions that disrupt thoughts, emotions, or behaviors, causing distress or impairment. The rise in psychological disorders is driven by stress, social isolation, economic pressures, genetics, substance abuse, and digital overuse. Central nervous system (CNS) lymphoma advances neuro-oncology research, improving understanding of brain inflammation, immune interactions, and the blood-brain barrier, which aids in developing better treatments for both cancer and psychological disorders. For instance, in 2024, according to the National Alliance On Mental Illness, a US-based organization, among people in the U.S. aged 18-44, psychosis spectrum and mood disorders account for nearly 600,000 hospitalizations each year. Therefore, increasing incidents of psychological disorders are driving growth in the central nervous system (CNS) lymphoma market.
Rising Prevalence Of Neurological Disorders Fuels Demand For Market
The rising prevalence of neurological disorders is expected to propel the growth of the central nervous system (CNS) lymphoma market going forward. Neurological disorders refer to any conditions that affect the nervous system, which includes the brain, spinal cord, and nerves. The increasing prevalence of neurological disorders can be attributed to various factors, including genetic predisposition, infections, trauma, toxins, autoimmune responses, and degeneration. Central nervous system (CNS) lymphoma enhances research on brain function, immune response, and neuroinflammation, leading to improved diagnostics and treatments that also benefit patients with neurological disorders. For instance, in April 2022, according to the European Brain Council, a Belgium-based non-profit organization, over 600 neurological diseases and nearly 300 psychiatric conditions afflict millions globally, including 65 million with epilepsy. In Europe, 10.5 million people have dementia, with projections indicating a rise to 18.7 million by 2050. Therefore, the rising prevalence of neurological disorders is expected to drive the growth of the central nervous system (CNS) lymphoma market.
What is the segmentation for the central nervous system (cns) lymphoma market?
The central nervous system (CNS) lymphoma market covered in this report is segmented –
1) By Class Of Drugs: Monoclonal antibodies, Chemotherapeutic Agents, Corticosteroids
2) By Treatment: Chemotherapy, Radiation Therapy, Steroid Therapy, Targeted Therapy
3) By Application: Hospitals, Clinics, Ambulatory Surgical Services, Other Applications
Subsegments:
1) By Monoclonal Antibodies: Anti-CD20 Monoclonal Antibodies, Anti-PD-1 Monoclonal Antibodies, Other Targeted Monoclonal Antibodies
2) By Chemotherapeutic Agents: Alkylating Agents, Antimetabolites, Topoisomerase Inhibitors
3) By Corticosteroids: Dexamethasone, Prednisolone, Methylprednisolone
Order your report now for swift delivery
Who are the most influential companies in the central nervous system (cns) lymphoma market?
Major companies operating in the central nervous system (CNS) lymphoma market are F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Sanofi S.A., Novartis International AG, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Fresenius SE & Co. KGaA, Incyte Corporation, ONO PHARMA USA Inc., Kazia Therapeutics Limited, Simcere Pharmaceutical Group Limited, Karyopharm Therapeutics Inc., Nurix Therapeutics Inc., CNS Pharmaceuticals Inc., JW Therapeutics, PentixaPharm Pty Ltd, Cellectar Biosciences Inc.
What are the most influential trends expected to drive the central nervous system (cns) lymphoma market forward?
Major companies operating in the central nervous system (CNS) lymphoma market are focusing on developing innovative therapies such as Tirabrutinib for the treatment of primary central nervous system (CNS) lymphoma. Tirabrutinib is a highly selective Bruton’s tyrosine kinase (BTK) inhibitor developed for the treatment of B-cell malignancies, including primary central nervous system lymphoma (PCNSL), by targeting pathways critical to cancer cell survival and proliferation. For instance, in March 2023, ONO Pharma Inc., a US-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation to tirabrutinib (ONO-4059) for treating primary central nervous system lymphoma (PCNSL). This is currently under investigation in the phase 2 PROSPECT study (NCT04947319), tirabrutinib is a potent, selective BTK inhibitor targeting B-cell proliferation and survival. Tirabrutinib regulates cellular proliferation and activation through the B-cell receptor, enabling survival, differentiation, and clonal expansion of B-cells.
What are the major regional insights for the central nervous system (cns) lymphoma market, and which region holds the top position?
North America was the largest region in the central nervous system (CNS) lymphoma market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the central nervous system (CNS) lymphoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
What Does The Central Nervous System (CNS) Lymphoma Market Report 2025 Offer?
The central nervous system (cns) lymphoma market research report from The Business Research Company offers global market size, growth rate, regional shares, competitor analysis, detailed segments, trends, and opportunities.
Central nervous system (CNS) lymphoma is a rare and aggressive type of lymphoma that originates in the brain or spinal cord. Its treatment aims to target and shrink cancerous cells in the CNS, alleviate symptoms, and improve survival rates through a combination of medications, targeted therapies, and focused high-energy treatments.
Purchase the exclusive report now to unlock valuable market insights:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=21133
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.
Our flagship product, the Global Market Model, is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
